Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies

Cancer Research

Volumn 59, Issue 16, 1999, Pages 3861-3865

  Aghi, Manish ^a   Chou, Ting Chao ^b   Suling, Kristen ^a   Breakefield, Xandra O ^a   Chiocca, E Antonio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Weill Cornell Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GANCICLOVIR; ONCOLYTIC VIRUS; OXAZAPHOSPHORINE DERIVATIVE; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CELL DEATH; CROSS LINKING; DRUG EFFECT; GENE THERAPY; GROWTH INHIBITION; HERPES SIMPLEX VIRUS; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIOMA; HUMANS; MICE; MICE, NUDE; RATS; THYMIDINE KINASE; TUMOR CELLS, CULTURED; VIRUS REPLICATION; VIRUSES;

EID: 0344200002     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943, 1995.
2. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
3. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. Reovirus therapy of tumors with activated Ras pathway. Science (Washington DC), 282: 1332-1334, 1998.
4. Chase, M., Chung, R. Y., and Chiocca, E. A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol., 16: 444-448, 1998.
5. Goldstein, D. J., and Weller, S. K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology, 166: 41-51, 1988.
6. Clarke, L., and Waxman, D. J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res., 49: 2344-2350, 1989.
7. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K., Kowall, N. W., Hochberg, F. H., Waxman, D. J., Breakefield, X. O., and Chiocca, E. A. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther., 5: 969-978, 1994.
8. Chen, L., and Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55: 581-589, 1995.
9. Chen, L., Yu, L. J., and Waxman, D. J. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res., 57: 4830-4837, 1997.
10. Boviatsis, E. J., Park, J. S., Sena-Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., Wei, M. X., Breakefield, X. O., and Chiocca, E. A. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res., 54: 5745-5751, 1994.
11. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., and Huang, H. J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA, 91: 7727-7731, 1994.
12. Goldstein, D. J., and Weller, S. K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol., 62: 196-205, 1988.
13. Chou, T. C. The median-effect principle and the combination index for quantification of synergism and antagonism. In: T. C. Chou and D. C. Rideout (eds.). Synergism and Antagonism in Chemotherapy, pp. 61-89. New York: Academic Press, 1991.
14. Aghi, M., Kramm, C. M., Chou, T. C., Breakefield, X. O., and Chiocca, E. A. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/ cytosine deaminase gene therapies. J. Natl. Cancer Inst., 90: 370-380, 1998.
15. Andersson, B. S., Sadeghi, T., Siciliano, M. J., Legerski, R., and Murray, D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother. Pharmacol., 38: 406-416, 1996.
16. Hindges, R., and Hubscher, U. DNA polymerase δ, an essential enzyme for DNA transactions. Biol. Chem., 378: 345-362, 1997.
17. Ilsley, D. D., Lee, S. H., Miller, W. H., and Kuchta, R. D. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry, 34: 2504-2510, 1995.
18. Yang, L. Y., Li, L., Keating, M. J., and Plunkett, W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol. Pharmacol., 47: 1072-1079, 1995.
19. Koehl, U., Li, L., Nowak, B., Ruiz van Haperen, V., Kornhuber, B., and Schwabe, D. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Proc. Am. Assoc. Cancer Res., 38: 2, 1997.
20. Keda, K., and Chiocca, E. A. Oncolytic virus therapy of multiple brain tumors requires suppression of innate and elicited immune responses. Nat. Med., in press, 1999.
21. Carroll, N. M., Chase, M., Chiocca, E. A., and Tanabe, K. K. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res., 69: 413-417, 1997.